TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10868832

Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Nateglinide 180 mg
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 9213836

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 26
Study: 8444727

Group type: EXPERIMENTAL
Intervention: High total work-exercise protocol [1 min rest, 10 RM load (H10/1)]
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All heavy-resistance exercise protocols
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: H10/1 protocol
Number of subjects: 8
Study: 3536640

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 29049845

Group type: EXPERIMENTAL
Intervention: Exercise intervention group (IG) performing endurance, strength, and flexibility training three times per week
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (CG) with a nonexercise program
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Exercise intervention group (IG)
Number of subjects: 53
Study: 26949110

Group type: EXPERIMENTAL
Intervention: Ovarian stimulation with clomiphene citrate, letrozole, or gonadotropins for up to four cycles or until pregnancy was achieved
Number of subjects: 900
Study: 25564086

Group type: EXPERIMENTAL
Intervention: Susceptibles
Number of subjects: 37

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 37
Study: 22735461

Group type: EXPERIMENTAL
Intervention: R1663 after a high fat/high calorie breakfast
Number of subjects: 8

Group type: COMPARATOR
Intervention: R1663 after an overnight fast of 10 h
Number of subjects: 8
Study: 20446252

Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine gel (10 cc of 2% lidocaine)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block (10 cc of 1% lidocaine solution)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (10 cc of ultrasound gel)
Number of subjects: 100
Study: 18782804

Group type: EXPERIMENTAL
Intervention: 360 degrees laser retinopexy
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 303
Study: 15830637

Group type: EXPERIMENTAL
Intervention: IL-1RN gene polymorphism
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: IL-1B-511 gene polymorphism
Number of subjects: 96
Study: 14655739

Group type: EXPERIMENTAL
Intervention: FCDS‐DC (GamCath Dolphin GDK 11 French, length 12.5 or 15 cm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: STD‐DC (GamCath GDK 11 French, length 12.5 or 15 cm)
Number of subjects: 20
Study: 10786218

Group type: EXPERIMENTAL
Intervention: CYP2D6 polymorphic alleles identified using allele specific nested PCR reaction
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 22
Study: 8912802

Group type: EXPERIMENTAL
Intervention: 20% nitrous oxide
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 60% nitrous oxide
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 80% nitrous oxide
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo oxygen
Number of subjects: 11
Study: 1833126

Group type: EXPERIMENTAL
Intervention: Low dose oral contraceptives (20 micrograms ethinyl estradiol and 150 micrograms desogestrel per day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High dose oral contraceptives (50 micrograms ethinyl estradiol and 125 micrograms desogestrel per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (before drug ingestion)
Number of subjects: 20
Study: 6285744

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (1.25 mg daily, orally)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol (5 gm ointment, 3 mg E2, applied each evening)
Number of subjects: 18
Study: 31140202

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Metformin intervention
Number of subjects: 333

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 333
Study: 28901333

Group type: EXPERIMENTAL
Intervention: Paleolithic-type diet (PD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nordic Nutrition Recommendations (NNR) diet
Number of subjects: 70
Study: 26245498

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRHa) goserelin, which causes a net decrease in sex-steroid levels.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRHa) goserelin
Number of subjects: 58
Study: 25267532

Group type: EXPERIMENTAL
Intervention: Carers' assessment, skills and information sharing (C) intervention + treatment as usual (TAU)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 178
Study: 22253096

Group type: EXPERIMENTAL
Intervention: Clinical overvaluation of shape and weight (determined by EDE)
Number of subjects: 116
Study: 20659948

Group type: EXPERIMENTAL
Intervention: Dior PCB
Number of subjects: 57

Group type: COMPARATOR
Intervention: Taxus DES
Number of subjects: 57
Study: 17287932

Group type: EXPERIMENTAL
Intervention: Probiotic Escherichia coli Nissle 1917 (EcN) solution, 1-3 ml per day (10^8 viable EcN cells per millilitre)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo suspension
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Probiotic Escherichia coli Nissle 1917 (EcN) solution
Number of subjects: 113
Study: 16146477

Group type: EXPERIMENTAL
Intervention: 26G Atraucan spinal needle
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 27G Whitacre spinal needle
Number of subjects: 303

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 303
Study: 12811371

Group type: EXPERIMENTAL
Intervention: Serotonin treatment
Number of subjects: 30
Study: 10556126

Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg by mouth, every 8 hours for 3 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8693526

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 10
Study: 2015395

Group type: EXPERIMENTAL
Intervention: IDR/Ara‐C
Number of subjects: 130

Group type: COMPARATOR
Intervention: DNR/Ara‐C
Number of subjects: 130
Study: 6177441

Group type: EXPERIMENTAL
Intervention: Aprotinin therapy added to hypovolaemia treatment
Number of subjects: 70
Study: 30865917

Group type: EXPERIMENTAL
Intervention: Oral targeted therapy or chemotherapy
Number of subjects: 181
Study: 28461543

Group type: EXPERIMENTAL
Intervention: Music listening (self-initiated, patient-directed via headphones)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Anxiety levels (measured daily with a visual analog scale)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Sedative exposure (daily sedation intensity score and sedative dose frequency)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Clinical factors (illness severity, days of weaning trials, tracheostomy placement)
Number of subjects: 307
Study: 26355168

Group type: EXPERIMENTAL
Intervention: Bone substitute covered with a resorbable membrane (BG group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Open flap debridement (OFD group)
Number of subjects: 97
Study: 23806013

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral techniques combined with virtual reality, biofeedback, and mobile phone.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Traditional stress management CBT-based training without the use of new technologies.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Waiting list group reassessed after five weeks, then randomly assigned to one of the two treatments.
Number of subjects: 150
Study: 21993933

Group type: EXPERIMENTAL
Intervention: LESS cholecystectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard four-port laparoscopic cholecystectomy
Number of subjects: 40
Study: 19241361

Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration adsorption (CPFA)
Number of subjects: 7

Group type: COMPARATOR
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 7
Study: 18039105

Group type: EXPERIMENTAL
Intervention: Recent advances in understanding the genetics of IBD and the immunology of host‐microbial interaction.
Number of subjects: 0
Study: 10764365

Group type: EXPERIMENTAL
Intervention: Nurse management
Number of subjects: 1815

Group type: COMPARATOR
Intervention: General practitioner management
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: Nurse consultations
Number of subjects: 1815

Group type: COMPARATOR
Intervention: Doctor consultations
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: Nurse prescriptions
Number of subjects: 1815

Group type: COMPARATOR
Intervention: Doctor prescriptions
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: Nurse management without doctor input
Number of subjects: 1815
Study: 8968035

Group type: EXPERIMENTAL
Intervention: Clodronate 1600 mg daily by mouth
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 1293650

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg) - two doses (the previous night and before surgery)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg) - two doses (the previous night and before surgery)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg) - the night prior to surgery
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg) - the night before
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg) - two doses (the previous night and before surgery)
Number of subjects: 105
Study: 6085358

Group type: EXPERIMENTAL
Intervention: Nifedipine (1.0 mg intravenous)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nitrendipine (1.0 mg intravenous)
Number of subjects: 6
Study: 31441401

Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30292081

Group type: EXPERIMENTAL
Intervention: CPAP + PR
Number of subjects: 40

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 40
Study: 26773917

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy plus physical exercise (n=7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Only pharmacotherapy (n=7)
Number of subjects: 14
Study: 24559809

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (H)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: NRT with Hypnotherapy (HNRT)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Self-quit group
Number of subjects: 164
Study: 22588010

Group type: EXPERIMENTAL
Intervention: Brief intensified cognitive behavioral therapy (CBT) and/or pharmacotherapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 500
Study: 20430686

Group type: EXPERIMENTAL
Intervention: Pressure Pain Threshold (PPT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Manual Palpation (MP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Algometry
Number of subjects: 30
Study: 18018782

Group type: EXPERIMENTAL
Intervention: Diprivan/Ketamine (D/K)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam/Ketamine (M/K)
Number of subjects: 60
Study: 15692141

Group type: COMPARATOR
Intervention: APAP alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: APAP + DPH
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: APAP + OXY
Number of subjects: 10
Study: 12239942

Group type: EXPERIMENTAL
Intervention: 5‐isosorbide mononitrate (80 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol (added after 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10428402

Group type: EXPERIMENTAL
Intervention: Phonologic speech intervention (SI)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Articulatory speech intervention (SI)
Number of subjects: 29
Study: 7671352

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 182

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 182
Study: 2147621

Group type: EXPERIMENTAL
Intervention: 40‐80 mg ketanserin daily for 4 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30487058

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin therapy for primary prevention of atherosclerotic events
Number of subjects: 1825

Group type: EXPERIMENTAL
Intervention: Age and long history of diabetes
Number of subjects: 1825
Study: 28862406

Group type: EXPERIMENTAL
Intervention: Symbiosal (NaCl + Chitosan 3%)
Number of subjects: 41

Group type: COMPARATOR
Intervention: NaCl (standard table marine salt)
Number of subjects: 41
Study: 26072302

Group type: EXPERIMENTAL
Intervention: Periarticular anesthesia (ropivacaine 1% 20 mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral and intravenous analgesia alone
Number of subjects: 0
Study: 24246210

Group type: EXPERIMENTAL
Intervention: Imidafenacin 0.1 mg twice daily for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fesoterodine 4 mg once daily for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imidafenacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fesoterodine
Number of subjects: 0
Study: 22047071

Group type: EXPERIMENTAL
Intervention: Television Assisted Prompting (TAP)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Typical (TYP) practice (without TAP reminders)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Self-selected preferred tasks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Self-selected non-preferred tasks
Number of subjects: 23
Study: 20033133

Group type: EXPERIMENTAL
Intervention: QSU-brief
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MPSS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CR
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MNWS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (continued smoking)
Number of subjects: 60
Study: 17692977

Group type: EXPERIMENTAL
Intervention: Preoperative 5x5Gy irradiation followed by surgery within 7 days
Number of subjects: 316

Group type: COMPARATOR
Intervention: Chemoradiation (50.4 Gy, 1.8Gy per fraction plus boluses of 5‐fluorouracil and leucovorin) followed by surgery after 4‐6 weeks
Number of subjects: 316
Study: 15884761

Group type: EXPERIMENTAL
Intervention: c9,t11 CLA
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: t10,c12 CLA
Number of subjects: 25

Group type: COMPARATOR
Intervention: Oleic acid
Number of subjects: 25
Study: 12473833

Group type: EXPERIMENTAL
Intervention: d4T (stavudine) in combination with lamivudine and indinavir
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: ZDV (zidovudine) in combination with lamivudine and indinavir
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (susceptible virus)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (resistant virus)
Number of subjects: 155
Study: 9796224

Group type: EXPERIMENTAL
Intervention: Exposure to melodies (study phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetition of studied melodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study-to-test changes in melody timbre and manipulation of study tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affect task
Number of subjects: 0
Study: 7785684

Group type: EXPERIMENTAL
Intervention: Artificial tears instillation in normal eyes
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Artificial tears instillation in postkeratoplasty eyes
Number of subjects: 38
Study: 2552342

Group type: EXPERIMENTAL
Intervention: yohimbine
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study: 510206

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum immune stimulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: VAC chemotherapy (vincristin, adriamycin, cyclophosphamide)
Number of subjects: 120

Group type: COMPARATOR
Intervention: FMC chemotherapy (fluorouracil, methotrexate, cyclophosphamide)
Number of subjects: 120
Study: 31418908

Group type: EXPERIMENTAL
Intervention: e-CBT (cognitive behavioural therapy with an email-based recording and reminding system for 20 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: s-CBT (cognitive behavioural therapy with a sticky note reminder for 20 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (simple verbal instructions to avoid nFTC for 20 days)
Number of subjects: 30
Study: 31257096

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the subthalamic nucleus (STN‐DBS)
Number of subjects: 114
Study: 29143799

Group type: EXPERIMENTAL
Intervention: Partially hydrolysed whey protein formula supplemented with starch and Lactobacillus reuteri (DSM 17938)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard starter formula
Number of subjects: 80
Study: 25744688

Group type: EXPERIMENTAL
Intervention: Biofeedback plus transanal electrostimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy (diet, exercise, laxatives)
Number of subjects: 0
Study: 23791697

Group type: EXPERIMENTAL
Intervention: Chewing gum with CPP-ACP (trident total)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chewing gum without CPP-ACP (trident)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no chewing gum)
Number of subjects: 12
Study: 21906879

Group type: EXPERIMENTAL
Intervention: PC-PEP (Pain Consultation combined with Pain Education Program)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 72
Study: 19382493

Group type: EXPERIMENTAL
Intervention: Rapid Rhino Mannheim
Number of subjects: 32

Group type: COMPARATOR
Intervention: Netcell Series 5000
Number of subjects: 32
Study: 17028770

Group type: EXPERIMENTAL
Intervention: Mammography plus sonography
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Physical examination plus mammography and sonography
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Physical examination
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Mammography and sonography
Number of subjects: 162
Study: 15042229

Group type: COMPARATOR
Intervention: Insecticide-treated curtains (ITC) provided to half the population in 1994, with re-treatment or replacement annually.
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Control group (no ITC provided until 1996).
Number of subjects: 100000
Study: 11033398

Group type: EXPERIMENTAL
Intervention: Amvisc Plus (sodium hyaluronate 1.6%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: OcuCoat (hydroxypropyl methylcellulose 2%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Viscoat (chondroitin sulfate 4%-sodium hyaluronate 3%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (BCVA worse than 20/40)
Number of subjects: 50
Study: 9314450

Group type: EXPERIMENTAL
Intervention: Clarithromycin/clofazimine (Clm/Clof)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Clarithromycin/rifabutin/ethambutol (Clm/Rib/Eth)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 144
Study: 8400255

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) for 70 days
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 3518625

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Ampicillin (4 g)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 94
Study: 28805066

Group type: EXPERIMENTAL
Intervention: Physiotherapy with ACM device
Number of subjects: 50
Study: 27136096

Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA) 1500mg/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA)
Number of subjects: 28
Study: 24396842

Group type: EXPERIMENTAL
Intervention: Laser-Lok type implants (n = 39)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Non-Laser-Lok type implants (n = 39)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77
Study: 22081867

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) containing ART regimen
Number of subjects: 46
Study: 20203244

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate, 200 microg twice a day for 3 days after 14 days of oxymetazoline
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intranasal oxymetazoline, 200 microg three times a day for 14 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oral prazosin, 1 mg
Number of subjects: 19
Study: 17653243

Group type: EXPERIMENTAL
Intervention: Angiotensin inhibition (ACE inhibitor or angiotensin receptor blocker)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No angiotensin inhibition (Control)
Number of subjects: 102
Study: 15799687

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly, alone or in combination with methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 0
Study: 12553620

Group type: EXPERIMENTAL
Intervention: Optibond FL
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gluma One Bond
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Acid etching plus Clearfil SE Bond
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Prompt‐L‐Pop
Number of subjects: 70
Study: 10076315

Group type: EXPERIMENTAL
Intervention: Known midwife during antenatal care
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Known midwife during intrapartum care
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Known midwife during postpartum domiciliary care
Number of subjects: 410
Study: 7776222

Group type: EXPERIMENTAL
Intervention: Nonskid socks
Number of subjects: 0
Study: 2096746

Group type: EXPERIMENTAL
Intervention: Articaine HCl (Ultracaine DS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prilocaine HCl (Citanest Forte)
Number of subjects: 0